ClinicalTrials.gg
Not yet recruitingNCT07370818Updated Jan 27, 2026

To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

A Phase 2 interventional study of JPI-547 and Bevacizumab in Ovarian Cancer, sponsored by Onconic Therapeutics Inc.. Not yet recruiting at 1 site in South Korea. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by Onconic Therapeutics Inc. (part of Jeil Pharmaceutical Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
19 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies testing bevacizumab in Ovarian Neoplasms — 22 open to participants now, 32 under way, 9 of them phase 3. Bevacizumab · Ovarian Neoplasms.

Planned enrollment
40th of 106
81 · median 52
Started
2026
with 5 others
Phase 2
66 of 106
11 open now
Primary completion
2029-12
later than 26 of 31 live
Registered
101st of 106
by date

Among the 106 studies testing bevacizumab in Ovarian Neoplasms, this one is the 40th largest by planned enrollment, is one of 6 that started in 2026, is one of 66 in phase 2, reaches primary completion later than 26 of the 31 other live ones, and was the 101st registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

22 of the 106 studies testing bevacizumab in Ovarian Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 19 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies testing bevacizumab in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This study aims to to evaluate the efficacy, safety, and pharmacokinetics of JPI- 547 with bevacizumab maintenance therapy in relapsed ovarian cancer patients

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer [High-grade serous carcinoma (HGSC), Grade 2/3 endometrioid carcinoma]
  • Patients whose BRCA 1/2 gene mutation status and/or Homologous Recombination Deficiency (HRD) status.
  • Patients who received platinum-based chemotherapy followed by PARP inhibitor maintenance therapy,
  • Patients who had received chemotherapy before participating in the clinical trial and responded to platinum-based chemotherapy.
  • Those with (ECOG) performance status 0 or 1.
  • Individuals with confirmed adequate hematological, renal, and hepatic function (laboratory tests may be repeated once during the screening period)

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of severe drug or hypersensitivity to the drug, its components, or drugs within the same class.
  • Individuals with dysphagia
  • Patients with a confirmed specific medical history or a past surgical history.
  • Patients with specific comorbidities or medical abnormalities.
  • Pregnant women, lactating women, or women of who do not agree to use appropriate during the clinical trial period and for 24 weeks after administration of the investigational medicinal product.
  • Those who have administered other investigational products or have received investigational medical device procedures within 4 weeks of the baseline
  • Other patients who are inappropriate or unable to participate in this clinical study at the discretion of the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
81 participants (estimated)

Study arms

  • Experimental
    JPI-547+Bevacizumab

    Drug: JPI-547 · Drug: Bevacizumab

  • Experimental
    Bevacizumab

    Drug: Bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: Maximum tolerated dose (MTD) and recommended dose (RD)(RP2D)

    Time frame: The dose-limiting toxicity evaluation window is 21 days

  2. Part B: Progression free survival(PFS)

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 74 months.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Dec 2029, 46 months later.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's planned 46 months is above that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
Jan 27, 2026
StartEst.
Feb 27, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2031
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07370818
Responsible party
Sponsor
First posted
Jan 27, 2026
Start date
Feb 27, 2026 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Jan 27, 2026

Study contacts

Onconic Therapeutics Inc.
Contact
onconictherapeutics@gmail.com
+ 82-2-3454-0780

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion